Despite some recent setbacks to its sickle cell disease (SCD) pipeline, Pfizer is plowing ahead in improving education around ...

Before joining Priovant, the new Abcuro executive spent more than a decade at Genzyme before its acquisition by Sanofi, ...

A new era of hypertension treatment is on the horizon for U.S. | The drug is the first triple-combo pill for the initial ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

After two years of quietly shifting its medical affairs and commercial strategy units under one roof, Astellas is entering a ...

After delivering strong sales growth last year and with more expansion in mind, CDMO giant Wuxi Biologics is breaking ground ...

Rechon Life Sciences, a Sweden-based pharma contract manufacturer, was hit with a warning letter from the FDA following an ...

As radiopharmaceutical therapies gain momentum, new challenges are emerging in how they’re administered—especially around ...

In its continued bid to waylay the launch of MSN Pharmaceuticals’ proposed Entresto generic, Novartis has told a federal ...

Researchers have zeroed in on yet another possible ocular concern for diabetes patients who take popular GLP-1 therapies in a ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...